Shanghai RAAS Blood Products Co Ltd Class A Market Cap ($4.56 Billion)
Market Cap & Net Worth: Shanghai RAAS Blood Products Co Ltd Class A (002252)
Shanghai RAAS Blood Products Co Ltd Class A market cap. Shanghai RAAS Blood Products Co Ltd Class A (SHE:002252) has a market capitalization of $4.56 Billion (CN¥31.18 Billion) as of November 1, 2026. Listed on the SHE stock exchange, this China-based company holds position #3654 globally and #453 in its home market, demonstrating a -1.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai RAAS Blood Products Co Ltd Class A's stock price CN¥4.73 by its total outstanding shares 6592672885 (6.59 Billion). Also see 002252 cash flow metrics for how efficiently the company converts equity into cash flow.
Shanghai RAAS Blood Products Co Ltd Class A Market Cap History (2015–2026)
Shanghai RAAS Blood Products Co Ltd Class A market cap history from 2015 to 2026. Data shows change from $20.76 Billion to $4.56 Billion (-13.31% CAGR). Check today's stock price for Shanghai RAAS Blood Products Co Ltd Clas for real-time trading data and today's change.
Shanghai RAAS Blood Products Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Shanghai RAAS Blood Products Co Ltd Clas to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.83x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 0.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.88x
Shanghai RAAS Blood Products Co Ltd Class A's market cap is 3.88 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $21.73 Billion | $2.33 Billion | $1.61 Billion | 9.34x | 13.47x |
| 2017 | $18.71 Billion | $1.93 Billion | $835.83 Million | 9.70x | 22.38x |
| 2018 | $7.56 Billion | $1.80 Billion | -$1.52 Billion | 4.19x | N/A |
| 2019 | $7.00 Billion | $2.58 Billion | $607.89 Million | 2.71x | 11.51x |
| 2020 | $6.99 Billion | $2.76 Billion | $1.32 Billion | 2.53x | 5.28x |
| 2021 | $6.46 Billion | $4.29 Billion | $1.29 Billion | 1.51x | 4.99x |
| 2022 | $6.03 Billion | $6.57 Billion | $1.88 Billion | 0.92x | 3.21x |
| 2023 | $7.65 Billion | $7.96 Billion | $1.78 Billion | 0.96x | 4.30x |
| 2024 | $6.97 Billion | $8.18 Billion | $2.19 Billion | 0.85x | 3.18x |
| 2025 | $6.12 Billion | $7.35 Billion | $1.58 Billion | 0.83x | 3.88x |
Competitor Companies of 002252 by Market Capitalization
Companies near Shanghai RAAS Blood Products Co Ltd Class A in the global market cap rankings as of November 1, 2026. Also see Shanghai RAAS Blood Products Co Ltd Clas (002252) total assets for a full breakdown of the balance sheet.
Key companies related to Shanghai RAAS Blood Products Co Ltd Class A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Shanghai RAAS Blood Products Co Ltd Class A (2015–2026)
Market capitalization of Shanghai RAAS Blood Products Co Ltd Class A from 2015 to today. Between 2015 and today, Shanghai RAAS Blood Products Co Ltd Class A's market cap moved from $20.76 Billion to $ 4.56 Billion, with a yearly change of -13.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.56 Billion | -25.39% |
| 2025 | CN¥6.12 Billion | -12.19% |
| 2024 | CN¥6.97 Billion | -8.91% |
| 2023 | CN¥7.65 Billion | +26.72% |
| 2022 | CN¥6.03 Billion | -6.60% |
| 2021 | CN¥6.46 Billion | -7.53% |
| 2020 | CN¥6.99 Billion | -0.18% |
| 2019 | CN¥7.00 Billion | -7.37% |
| 2018 | CN¥7.56 Billion | -59.61% |
| 2017 | CN¥18.71 Billion | -13.90% |
| 2016 | CN¥21.73 Billion | +4.65% |
| 2015 | CN¥20.76 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Shanghai RAAS Blood Products Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.56 Billion USD |
| MoneyControl | $4.56 Billion USD |
| MarketWatch | $4.56 Billion USD |
| marketcap.company | $4.56 Billion USD |
| Reuters | $4.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinoge… Read more